NanoMedicine Labs
NanoMedicine Labs Raises $460M Series C to Transform Healthcare
Quick Facts
NanoMedicine Labs
Breakthrough nanoscale drug delivery systems enabling targeted cancer treatment with 95% reduced side effects.
About the Funding
NanoMedicine Labs has successfully raised $460M in a Series C funding round, bringing their total valuation to $5.8B. This significant investment will fuel the company's mission to advance phase iii clinical trials, scale manufacturing capabilities, and expand pipeline to rare diseases.
Use of Funds
Advance Phase III clinical trials, scale manufacturing capabilities, and expand pipeline to rare diseases
Company Overview
Breakthrough nanoscale drug delivery systems enabling targeted cancer treatment with 95% reduced side effects.
Key Investors
- • Johnson & Johnson Innovation
- • Roche Ventures
- • RA Capital
- • Flagship Pioneering
Founders
- • Dr. Jennifer Liu
- • Dr. Robert Kim
Previous Rounds
Market Impact
This funding round positions NanoMedicine Labs as a leader in the Biotech space, with the capital to accelerate innovation and expand their market presence. The investment reflects growing confidence in healthcare solutions and the company's potential to transform the industry.
Key Investors
About the Author
Related Company Reports
BioAge Therapeutics Raises $350M Series C to Transform Healthcare
BioAge Therapeutics secures $350M in Series C funding at $4.3B valuation to advance anti-aging drug trials, expand research into age-related diseases, and scale manufacturing for clinical studies.
NeuroPharma raises $190M Series B in September 2025 funding round
NeuroPharma secures $190M in Series B funding in September 2025, reaching $1.6B valuation to advance its neurological drug discovery using ai and machine learning.
BioSynth Labs raises $380M Series B in September 2025 funding round
BioSynth Labs secures $380M in Series B funding in September 2025, reaching $3.2B valuation to advance its synthetic biology platform for sustainable chemical manufacturing.
